

TREBALL DE FI DE GRAU

BACHELOR'S DEGREE OF BIOCHEMISTRY AND MOLECULAR BIOLOGY


COMPARATIVE ANALYSIS OF DIFFERENT RISK STRATIFICATION MODELS FOR SMOLDERING MULTIPLE MYELOMA APPLIED TO PATIENTS AT THE JOAN XXIII HOSPITAL IN TARRAGONA

AUTHOR: Alba Soledad Rodríguez Raya

TUTORA PROFESIONAL: Margarida María Terrón Puig

TUTOR ACADÉMICO: Enrique Calvo Manso

Tarragona, June 2022



UNIVERSITAT
ROVIRA i VIRGILI

HJ23

Hospital Universitari Joan XXIII
ICS Camp de Tarragona

This project is based on the results obtained during my curricular internship at the Clinical Laboratory of the Joan XXIII University Hospital in Tarragona.

First of all, I would like to sincerely show my gratitude to the director of the Laboratori Clínic ICS Camp de Tarragona i Terres del Ebre, Dr. Maria Teresa Sans Mateu, for allowing me to do my internship and the final degree project in the clinical laboratory. I would like to express my warm thank to Dr. Margarida María Terrón Puig, for guiding me every time I needed during these practices. Her support, her help and her dedication has been essential to achieve this project. I would also like to thank all the members of the clinical laboratory I've been working with, especially Dr. María Carmen Molina Clavero, for the support received at any time; and Dr. Juan Camilo Restrepo Correa, for their help with the patients' database. They accepted me as a part of the group for the first day I arrived.

Finally, I want to thank Dr. Enrique Calvo Manso, for the help received during the writing of this project and for the time he spent on correcting this project.

The content of this final degree project is confidential, for further information please contact: albasoledad.rodriquez@estudiants.urv.cat

INDEX

ABSTRACT	4
GLOSSARY OF ABBREVIATIONS	5
1. INTRODUCTION	6
A. DEFINITION OF THE DIFFERENT ENTITIES	6
- Smoldering multiple myeloma (SMM)	7
- Multiple myeloma (MM)	8
- Monoclonal gammopathy of uncertain significance (MGUS)	9
B. RISK STRATIFICATION MODELS FOR PROGRESSION TO MULTIPLE MYELOMA IN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA	10
C. DIAGNOSTIC TESTS PERFORMED IN THE CLINICAL LABORATORY	14
2. HYPOTHESES AND OBJECTIVES	16
3. METHODOLOGY	17
A. PATIENTS	17
B. STATISTICAL ANALYSIS	18
4. RESULTS	18
A. PATIENT CHARACTERISATION	18
B. CLASSIFICATION OF PATIENTS	19
C. COMPARISON OF RISK STRATIFICATION MODELS	21
D. PROGRESSION ANALYSIS IN HIGH-RISK GROUPS FOR EACH RISK STRATIFICATION MODEL	25
5. DISCUSSION	31
6. CONCLUSIONS	36
7. BIBLIOGRAPHY	37

Abstract

Background: Smoldering multiple myeloma (SMM) is an asymptomatic clinical precursor of multiple myeloma (MM). With the aim of delaying the onset of MM and improving its prognosis, experts have suggested treatment for those quiescent patients with a greater than 50% probability of progression. In recent years, different risk stratification models for SMM patients have emerged.

Objectives: This study proposes the evaluation and comparison of risk stratification models in patients with SMM at the Joan XXIII University Hospital. Subsequently, the progression of high-risk patients to MM in two years after diagnosis will be analyzed.

Methodology: A cohort of 42 smoldering patients from 2017 to 2022 was used to achieve these objectives. All information was collected on parameters related to disease progression. The different stratification models were applied to assess the risk of each patient and their progression to MM was evaluated over two years.

Results and conclusion: In this study it was found that the stratification models including cytogenetics achieved a more homogeneous classification of patients. At the same time, the IMWG model has the highest sensitivity, specificity and accuracy in patient's classification. However, further studies are needed to validate its use in clinical and diagnostic practice. Much more research is needed in this field to unify the definition of high-risk SMM patients and to transform the current treatment paradigm.

Keywords: smoldering multiple myeloma, multiple myeloma, monoclonal gammopathy of uncertain significance, risk stratification model, treatment, Mayo Clinic, Spanish Myeloma Group, International Myeloma Working Group.